Our Pipeline

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration.
This information is presented only for purposes of providing a general overview of our clinical trials only.

Wholly-owned U.S. Wholly-owned Collaboration
COMPOUND (Partner)
Phase 1 Phase 2 Phase 3
Or Registration Trial
Binimetinib (Ono, Pierre Fabre) Disease State: Cancer     Target: MEK
   
Encorafenib (Ono, Pierre Fabre) Disease State: Cancer     Target: BRAF
   
Selumetinib (AstraZeneca) Disease State: Cancer and NF1     Target: MEK
   
Ipatasertib (Genentech) Disease State: Cancer     Target: AKT
   
Varlitinib (ASLAN) Disease State: Cancer     Target: Pan-HER
   
Danoprevir (Roche) Disease State: Hepatitis C     Target: NS3 Protease
   
ARRY-797 Disease State: LMNA-related DCM     Target: p38
   
Larotrectinib* (Loxo Oncology) Disease State: Cancer     Target: PanTrk
  
Tucatinib* (Seattle Genetics) Disease State: Cancer     Target: HER-2
  
ARRY-382 Disease State: Cancer     Target: CSF1R
  
Motolimod (Celgene) Disease State: Cancer     Target: TLR
  
Prexasertib (Eli Lilly) Disease State: Cancer     Target: Chk1
  
GDC-0575 (Genentech) Disease State: Cancer     Target: Chk1
 
LOXO-292 (Loxo Oncology) Disease State: Cancer     Target: Ret
 
LOXO-195 (Loxo Oncology) Disease State: Cancer     Target: Trk
 
AK-1830 (Asahi Kasei Pharma) Disease State: Inflammation     Target: Trk
 

*Phase 2 registration trials

Continuing Medical Education / Grant Requests
Array BioPharma Guidelines for the Support of Independent Medical Education.pdf
CME@arraybiopharma.com

NOW ENROLLING

Learn more about the Phase 3
BEACON CRC trial